These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 14534918)

  • 21. Long-term adherence to apomorphine infusion in patients with Parkinson disease: a 10-year observational study.
    Kimber TE; Fang J; Huddy LJ; Thompson PD
    Intern Med J; 2017 May; 47(5):570-573. PubMed ID: 28145054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medication errors in Parkinson's disease inpatients in the Basque Country.
    Lertxundi U; Isla A; Solinís MÁ; Echaburu SD; Hernandez R; Peral-Aguirregoitia J; Medrano J; García-Moncó JC
    Parkinsonism Relat Disord; 2017 Mar; 36():57-62. PubMed ID: 28065403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.
    Hauser RA; Li R; Pérez A; Ren X; Weintraub D; Elm J; Goudreau JL; Morgan JC; Fang JY; Aminoff MJ; Christine CW; Dhall R; Umeh CC; Boyd JT; Stover N; Leehey M; Zweig RM; Nicholas AP; Bodis-Wollner I; Willis A; Kieburtz K; Tilley BC;
    J Parkinsons Dis; 2017; 7(1):117-127. PubMed ID: 27911341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subthalamic Nucleus Deep Brain Stimulation Alters Prefrontal Correlates of Emotion Induction.
    Bick SK; Folley BS; Mayer JS; Park S; Charles PD; Camalier CR; Pallavaram S; Konrad PE; Neimat JS
    Neuromodulation; 2017 Apr; 20(3):233-237. PubMed ID: 27730703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subthalamic Nucleus Deep Brain Stimulation for Parkinson Disease in Hong Kong: A Prospective Territory-Wide 2-Year Follow-Up Study.
    Chan DT; Zhu CX; Lau CK; Poon TL; Cheung FC; Lee M; Taw B; Hung KN; Choi P; AuYeung M; Chan G; Cheung YF; Chan AY; Yeung JH; Mok VC; Poon WS;
    World Neurosurg; 2016 Sep; 93():229-36. PubMed ID: 27297243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects.
    Simon DK; Simuni T; Elm J; Clark-Matott J; Graebner AK; Baker L; Dunlop SR; Emborg M; Kamp C; Morgan JC; Ross GW; Sharma S; Ravina B;
    J Parkinsons Dis; 2015; 5(4):731-6. PubMed ID: 26444095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, controlled trial of add-on therapy in moderate-to-severe Parkinson's disease.
    Zhao S; Cheng R; Zheng J; Li Q; Wang J; Fan W; Zhang L; Zhang Y; Li H; Liu S
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1214-8. PubMed ID: 26342560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deep brain stimulation may reduce the relative risk of clinically important worsening in early stage Parkinson's disease.
    Hacker ML; Tonascia J; Turchan M; Currie A; Heusinkveld L; Konrad PE; Davis TL; Neimat JS; Phibbs FT; Hedera P; Wang L; Shi Y; Shade DM; Sternberg AL; Drye LT; Charles D
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1177-83. PubMed ID: 26306000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anxiety-provoked gait changes are selectively dopa-responsive in Parkinson's disease.
    Ehgoetz Martens KA; Ellard CG; Almeida QJ
    Eur J Neurosci; 2015 Aug; 42(4):2028-35. PubMed ID: 25899750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does Dopamine Replacement Medication Affect Postural Sequence Learning in Parkinson's Disease?
    Hayes HA; Hunsaker N; Schaefer SY; Shultz B; Schenkenberg T; Boyd LA; White AT; Foreman KB; Dyer P; Maletsky R; Dibble LE
    Motor Control; 2015 Oct; 19(4):325-40. PubMed ID: 25823498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
    Liu C; Cholerton B; Shi M; Ginghina C; Cain KC; Auinger P; ; Zhang J
    Parkinsonism Relat Disord; 2015 Mar; 21(3):271-6. PubMed ID: 25596881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection.
    Hauser RA; Isaacson S; Clinch T;
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1171-6. PubMed ID: 25239603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased all-cause mortality with psychotropic medication in Parkinson's disease and controls: a national register-based study.
    Frandsen R; Baandrup L; Kjellberg J; Ibsen R; Jennum P
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1124-8. PubMed ID: 25164488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.
    Parashos SA; Luo S; Biglan KM; Bodis-Wollner I; He B; Liang GS; Ross GW; Tilley BC; Shulman LM;
    JAMA Neurol; 2014 Jun; 71(6):710-6. PubMed ID: 24711047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An exploratory study of the efficacy and safety of yokukansan for neuropsychiatric symptoms in patients with Parkinson's disease.
    Hatano T; Hattori N; Kawanabe T; Terayama Y; Suzuki N; Iwasaki Y; Fujioka T;
    J Neural Transm (Vienna); 2014; 121(3):275-81. PubMed ID: 24169925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study.
    Grosset KA; Malek N; Morgan F; Grosset DG
    J Parkinsons Dis; 2013; 3(1):31-7. PubMed ID: 23938309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subthalamic deep brain stimulation with a new device in Parkinson's disease: an open-label trial.
    Liu HG; Ma Y; Zhang K; Ge M; Meng FG; Feng T; Wan XH; Guo Y; Wang RZ; Yang AC; Hu WH; Guo JZ; Zhang JG
    Neuromodulation; 2013; 16(3):212-8; discussion 218. PubMed ID: 23551404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of forced-exercise therapy for Parkinson's disease on motor cortex functional connectivity.
    Beall EB; Lowe MJ; Alberts JL; Frankemolle AM; Thota AK; Shah C; Phillips MD
    Brain Connect; 2013; 3(2):190-8. PubMed ID: 23316956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease.
    Fukada K; Endo T; Yokoe M; Hamasaki T; Hazama T; Sakoda S
    Med Hypotheses; 2013 Feb; 80(2):209-12. PubMed ID: 23265352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.